Original articleClinical endoscopyComparing the number and relevance of false activations between 2 artificial intelligence computer-aided detection systems: the NOISE study
Section snippets
Methods
The study was approved by the local Institutional Review Board and registered on the ClinicalTrial.gov (NCT04399590). This was a no-profit study, and no funding was received or solicited, except the loan of the equipment by Fujifilm and Medtronic (CAD-EYE by Fuji and GI-Genius by Medtronic). All authors had access to the study data and reviewed and approved the final manuscript.
Results
Patient and procedural characteristics were comparable between the 2 groups (Table 2). At least 1 polyp was detected in 32 and 33 colonoscopies (P = .77) in the CADe A (CAD-EYE) and CADe B (GI Genius) groups, respectively. Overall, 80 polyps were detected in CADe A and 76 polyps were detected in CADe B with mean withdrawal times of 11.2 ± 4.2 minutes and 11.4 ± 3.9 minutes, respectively (P = .84).
A total of 1021 FP activations were registered across the 40 videos of CADe A, corresponding to a
Discussion
When comparing 2 different CADe brands, no difference in the rate of FP activations was observed, supporting the clinical equivalence of different CADe systems applied to screening and diagnostic colonoscopy. In addition, we showed a very narrow range of FP activations between 19 and 41 that may be adopted as a benchmark for other CADe systems in the future.
The clinical relevance of the equivalent performances of the 2 different CADe brands is primarily related to differences in terms of
References (28)
- et al.
Detection of colorectal adenomas with a real-time computer-aided system (ENDOANGEL): a randomised controlled study
Lancet Gastroenterol Hepatol
(2020) - et al.
Computer-aided detection versus advanced imaging for detection of colorectal neoplasia: a systematic review and network meta-analysis
Lancet Gastroenterol Hepatol
(2021) - et al.
AI in gastroenterology. The current state of play and the potential. How will it affect our practice and when?
Techn Gastrointest Endosc
(2020) - et al.
A primer of artificial intelligence in medicine
Techn Gastrointest Endosc
(2020) - et al.
Quality assurance of computer-aided detection and diagnosis in colonoscopy
Gastrointest Endosc
(2019) - et al.
New artificial intelligence system: first validation study versus experienced endoscopists for colorectal polyp detection
Gut
(2020) - et al.
Exploring the clinical potential of an automatic colonic polyp detection method based on the creation of energy maps
Endoscopy
(2016) - et al.
Artificial intelligence-assisted polyp detection for colonoscopy: initial experience
Gastroenterology
(2018) - et al.
Artificial intelligence technologies for the detection of colorectal lesions: the future is now
World J Gastroenterol
(2020) - et al.
Real-time automatic detection system increases colonoscopic polyp and adenoma detection rates: a prospective randomised controlled study
Gut
(2019)
Impact of a real-time automatic quality control system on colorectal polyp and adenoma detection: a prospective randomized controlled study (with videos)
Gastrointest. Endosc
Study on detection rate of polyps and adenomas in artificial-intelligence-aided colonoscopy
Saudi J Gastroenterol
Efficacy of real-time computer-aided detection of colorectal neoplasia in a randomized trial
Gastroenterology
Artificial intelligence and colonoscopy experience: lessons from two randomised trials
Gut
Cited by (0)
DISCLOSURE: The following authors disclosed financial relationships: C. Hassan, A. Repici: Consultant for Medtronic and Fuji. R. Maselli: Consultant for Fuji. S. Carrara, A. Anderloni: Consultant for Olympus Corp. Y. Mori: Consultant for Olympus Corp; ownership in Cybernet Corp. M. B. Wallace: Research funding from Medtronic; Research grants from Fujifilm, Boston Scientific, Olympus, Medtronic, Ninepoint Medical, and Cosmo/Aries Pharmaceuticals; Stock options in Virgo Inc; Minor food/beverage at meetings from Synergy Pharmaceuticals, Boston Scientific, and Cook Medical; Consultant on behalf of Mayo Clinic, paid to Mayo Clinic, for GI Supply (2018), Endokey, Endostart, Boston Scientific, Microtek, and Verily. All other authors disclosed no financial relationships.